Zentalis price target lowered to $9 from $10 at Oppenheimer

Oppenheimer lowered the firm’s price target on Zentalis (ZNTL) to $9 from $10 and keeps an Outperform rating on the shares after quarterly results and catching up with management. The firm believes Azenosertib is a drug that will help people with ovarian cancer. While Oppenheimer acknowledges the company likely won’t have any major clinical milestones, it notes that it should have an important regulatory milestone: FDA buy-in on a confirmatory trial design-which would mean implicit confirmation of azenosertib’s proposed accelerated approval pathway.